Lymphopenia is a condition in which there is a lower-than-normal number of lymphocytes (a type of white blood cell) in the blood. Also called lymphocytic leukopenia and lymphocytopenia.
A new study describes a synthetic peptide used as a platform to generate protective adaptive cellular immunity to the virus in rhesus macaques, which are the gold standard for preclinical testing in humans.
A team of scientists from the United States has recently compared the immune response elicited by natural severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) vaccination. Their findings reveal that, unlike vaccination, natural SARS-CoV-2 infection is associated with a robust interferon response together with an induction of cytotoxic gene expression in peripheral blood lymphocytes. The study is currently available on the medRxiv* preprint server.
A new research paper posted to the medRxiv* preprint server describes the changes in genomic sequence observed during the course of infection in a patient on the drug tacrolimus, along with steroids, both potent immunosuppressants, and who also received convalescent plasma treatment. These mutations were observed to occur within three weeks from infection.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive-sense single-stranded RNA virus that is contagious in humans. It is the causal agent of the ongoing coronavirus 2019 (COVID-19) pandemic. This virus causes a mild to severe infection and has claimed over 2.95 million lives worldwide. SARS-CoV-2 is the successor to SARS-CoV-1, the virus that caused the 2002–2004 SARS outbreak.
The gut is a well-established route of infection and target for viral damage by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent for COVID-19. This is supported by the clinical observation that about half of COVID-19 patients exhibit gastrointestinal (GI) symptoms.
In the study, which appeared on the pre-print server medRxiv, the team found that when the monkeys were reinfected, the T cell-depleted animals showed anamnestic immune responses, the enhanced reaction of the body's immune system to an antigen that is related to an antigen previously encountered.
The COVID-19 pandemic has claimed over 2.67 million lives in less than a year and a half. However, it is uncommon in children, with less than 2% of the cases being in individuals below the age of 19. Most of these are of mild severity, with the clinical features of severe COVID-19 being rare in this age group.
The ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread to over 192 countries and territories, causing an enormous loss of lives and economic devastation.
A team of researchers from the CHUM Research Centre has identified new biomarkers associated with the severity of COVID-19 in infected patients.
A team of researchers at Georgetown University Medical Center, USA, investigated how SARS-CoV-2 affects the immune system’s response during and after infection and contributes to the severity of COVID-19.
While primarily a respiratory illness, there are distinctive alterations in the type and number of blood cells in COVID-19. A new study by a team of researchers in Germany describes the nature of these changes.
To discriminate between patients with severe and non-severe COVID-19 quickly, researchers from Peru looked for prognostic signatures in the blood samples of COVID-19 patients. Virgilio E. Failoc-Rojas et al. examined laboratory results and clinical prognosis of COVID-19 patients from a hospital in the Peruvian Amazon.
Researchers at the University of California, Irvine set out to determine the differences between young people and older adults regarding their host responses against SARS-CoV-2. The team revealed that independent of disease severity, COVID-19 was linked to a significant shift in plasma inflammatory factors. The research is posted to the pre-print server medRxiv*.
A recent US study, currently available on medRxiv preprint server, supports a beneficial rather than immunopathologic role for effector T-cells during serious infections with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) –
A new study suggests that factor V, a coagulation factor, is upregulated in a range of white blood cells in severe COVID-19. This increase is linked to the observed coagulopathy, lymphopenia and suppression of adaptive immunity in such patients.
Researchers find that the presence of SARS-CoV-2's genetic material in the serum of positive patients could be a sturdy biomarker for predicting COVID-19-related mortality.
In a preprint paper published on the medRxiv server, a team of researchers from various institutions in South Africa, the UK, and Europe discuss how they determined the impact of HIV on the COVID-19 immune response in KwaZulu-Natal, South Africa, which is an area with very high HIV prevalence.
Researchers from the Huazhong University of Science and Technology and Shanghai Jiao Tong University, China, recently built a proteome microarray with 20 out of the 28 predicted SARS-CoV-2 proteins to help understand IgM/IgG responses specific to SARS-CoV-2.
A preliminary analysis of photon therapy treatment group 1 from the phase II NRG Oncology clinical trial NRG-BN001 indicates that there is no statistically significant overall survival (OS) or toxicity differences between dose-intensification radiation therapy (DI-RT) using intensity-modulated radiation therapy (IMRT) and standard-dose radiation therapy (SD-RT) with temozolomide treatments for patients with newly diagnosed glioblastoma (GBM).
A team of scientists from the United Kingdom has revealed that markers of endothelial cell injury are associated with severe and fatal outcome of coronavirus disease 2019 (COVID-19). The study is currently available on the medRxiv* preprint server.